Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)
Latest Information Update: 28 Dec 2020
At a glance
- Drugs Regorafenib (Primary) ; Tislelizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 21 Dec 2020 Status changed from not yet recruiting to recruiting.
- 04 Dec 2019 New trial record